Montelukast: Use in Pediatric Patients With Eosinophilic Gastrointestinal Disease

Vanderhoof, Jon A.; Young, Rosemary J.; Hanner, T. L.; Kettlehut, Brett

doi:10.1097/00005176-200302000-00027

Cited by 36 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…83 • Inflammatory bowel disease. 84,85 In conclusion, these new applications broaden the possible range of treatments for other allergic diseases beyond asthma. tileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.…”

Section: Other Uses For Lt Modifiersmentioning

confidence: 97%

Montelukast in allergic diseases beyond asthma

Leonardi

Marchese

Marseglia

et al. 2007

allergy asthma proc

View full text Add to dashboard Cite

Allergic diseases include a variety of different illnesses (rhinitis, conjunctivitis, asthma, urticaria, and dermatitis) in which the physiological and pathological basis is the release of chemical mediators such as histamine; platelet-activating factor; metabolites of arachidonic acid; and chemotactic factors from mastocytes, basophils, and eosinophils. The numerous drugs used for allergy treatment now include the new pharmacologic category of cysteinyl leukotriene (LT) antagonists. LTs are released from eosinophils, mast cells, and macrophages, interacting functionally in allergic reactions against a background of an imbalance between T-cell clones and resulting in preferential cytokine production following the T-helper 2 profile. Anti-LTs also have been used successfully by some authors to control rhinitis, atopic dermatitis, and urticaria. although additional controlled testing will be required, these applications broaden the possible range of treatments for allergic disease in all its many aspects.

show abstract

Section: Other Uses For Lt Modifiersmentioning

confidence: 97%

Montelukast in allergic diseases beyond asthma

Leonardi

Marchese

Marseglia

et al. 2007

allergy asthma proc

View full text Add to dashboard Cite

show abstract

“…[7,8] ECP can insert voltage insensitive, ion-nonselective toxic pores into the membranes of target cells and these pores may facilitate the entry of other toxic molecules. [9] MBP directly increases smooth muscle reactivity by causing dysfunction of vagal muscarinic M2 receptors. [10] MBP also triggers degranulation of mast cells and basophils.…”

Section: Function Of Eosinophilia In the Gastrointestinal Systemmentioning

confidence: 99%

Gastrointestinal Eosinophilia

Zuo

Rothenberg

2007

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

“…Cromolyn sodium was reported to be effective in one adult with eosinophilic gastroenteritis with protein-losing enteropathy [39]. The use of montelukast demonstrated limited effectiveness in treating adults with eosinophilic esophagitis [40], and its use in children with various gastrointestinal eosinophilic diseases is limited to a case series reporting clinical improvement but lacking histological follow-up [41].…”

Section: Mast Cell Stabilizers and Leukotriene Inhibitorsmentioning

confidence: 99%